KRAS and colonic neoplasm: We therefore designed the small molecule Cdc42 inhibitor AZA197 and show that inhibition of Cdc42 activity with AZA197 acts to reduce tumor growth and significantly improve animal survival in SW620 cells which are a model of KRAS mutant colon cancer xenografts [33].